Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results, Misses Estimates By $0.22 EPS

Mirum Pharmaceuticals (NASDAQ:MIRM) released its earnings results on Wednesday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22), Zacks reports. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%.

Mirum Pharmaceuticals Stock Performance

MIRM stock traded up $0.59 during trading on Wednesday, hitting $50.52. 486,456 shares of the company traded hands, compared to its average volume of 524,558. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $54.23. The stock’s 50-day simple moving average is $46.52 and its 200 day simple moving average is $43.27. The company has a market cap of $2.43 billion, a PE ratio of -25.01 and a beta of 0.96.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 9,102 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $438,898.44. Following the sale, the chief executive officer now directly owns 115,920 shares of the company’s stock, valued at $5,589,662.40. This trade represents a 7.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the completion of the transaction, the chief operating officer now directly owns 27,015 shares in the company, valued at $1,156,782.30. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,915 shares of company stock valued at $1,897,920 in the last quarter. Corporate insiders own 22.87% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.